Problem CCF (EF < 40%, NYHA II)
Format Multicenter, double-blind, randomized placebo-controlled trial
Treatment Low-dose Rosuvastatin (10mg)
Control Placebo
Population 5,011 patients
Inclusion criteria Age >60 years
Ischemic CHF
NYHA class II-IV symptoms
LVEF <40% (or <35% with NYHA class II symptoms)
No indication for cholesterol-lowering therapy
Stable on optimal treatment for >2 weeks prior to randomization
Exclusion criteria Prior statin-induced myopathy or hypersensitivity
Decompensated CHF or need for inotropic support
MI within past 6 months
UA or stroke within past 3 months
PCI, CABG, ICD, or BiV pacemaker within past 3 months or plan to implant
Prior heart transplant
Significant uncorrected primary valvular heart disease
Malfunctioning prosthetic valve
Hypertrophic cardiomyopathy
Acute endomyocarditis/myocarditis
Pericardial disease
Systemic disease (eg, amyloidosis)
Liver disease
Serum Cr >2.5 mg/dL
Chronic muscle disease or CPK > 2.5x ULN
Prior cyclosporine
Life-limiting condition limiting compliance with protocol
Receipt of <80% placebo tablets during run-in period
Follow-up Mean 2.7 years
Primary endpoint Composite of cardiovascular death, nonfatal MI, or nonfatal stroke
Secondary endpoint(s) All-cause mortality
Coronary events
Cardiovascular death
Details .
Brief summary: Rosuvastatin in statin-naive CCF patients reduced admissions but not mortality
PAPER: Rosuvastatin in older patients with systolic heart failure.
Date 29 Nov 2007
Journal N Engl J Med. 2007 Nov 29;357(22):2248-61. Epub 2007 Nov 5.
Information In those with CCF and no other indication for statins, Rosuvastatin 10mg:
-No improval in survival
-Reduced hospital admissions (p<0.001)